What nephrologists need to know about gadolinium

@article{Penfield2007WhatNN,
  title={What nephrologists need to know about gadolinium},
  author={Jeffrey G. Penfield and Robert F. Reilly},
  journal={Nature Clinical Practice Nephrology},
  year={2007},
  volume={3},
  pages={654-668}
}
Gadolinium chelates are commonly used to improve tissue contrast in MRI. Until recently the use of gadolinium was thought to be risk-free compared with alternative contrast agents. Recent studies, however, have raised serious concerns regarding the safety of gadolinium chelates. Although safe in patients with normal kidney function, administration of these agents in people with renal dysfunction can result in up to three clinical problems that the nephrologist should be familiar with. The first… Expand
Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
TLDR
Despite the NSF risk, contrast-enhanced MRI is a safe diagnostic procedure which can be used reliably and safely even in patients with severe renal failure, and does not necessarily have to be replaced by other methods. Expand
Gadolinium-Induced Fibrosis.
TLDR
It is proposed that the name gadolinium-induced fibrosis (GIF) more accurately reflects the totality of knowledge regarding this disease and use of high-risk GBCAs, such as formulated gadodiamide, should be avoided in patients with renal disease. Expand
Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents
Nephrogenic systemic fibrosis (NSF) is a disease seen exclusively in patients with decreased renal function. The use of gadolinium-based contrast agents (GBCAs) has a strong association with NSF.Expand
Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.
TLDR
Development of NSF was strongly associated with gadodiamide administration in the setting of either acute hepatorenal syndrome or dialysis-dependent chronic renal insufficiency. Expand
Gadolinium-associated plaques: a new, distinctive clinical entity.
TLDR
Doctors should be aware that GAP can occur without NSF or renal disease and is associated with the use of radiologic dyes, which is related to a particular type of gadolinium used for contrast-enhanced radiologic studies. Expand
Is it safe to use gadolinium-based contrast agents in MRI?
  • R. Pullicino, K. Das
  • Medicine
  • The journal of the Royal College of Physicians of Edinburgh
  • 2017
TLDR
The development of the gadolinium contrast agents, their use and the advice related to this new information are reviewed. Expand
Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
TLDR
To reduce the risk of NSF, renal function must be determined before exposure to gadolinium-containing MR contrast agents, and a sufficient period of time for elimination of the contrast agent from the body should be allowed before readministration of the Contrast agent. Expand
Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities.
TLDR
The benchmark incidence of nephrogenic systemic fibrosis related to the confirmed use of different gadolinium chelate contrast agents at four U.S. university tertiary care centers was much greater at the two centers where gadodiamide was used than at theTwo center where gadopentetate dimeglumine was used. Expand
Pathogenesis, Diagnosis, and Therapy
TLDR
To reduce the risk of NSF, renal function must be determined before exposure to gadolinium-containing MR contrast agents, and a sufficient period of time for elimination of the contrast agent from the body should be allowed before readministration of the Contrast Agent. Expand
Gadolinium and nephrogenic systemic fibrosis.
  • V. Runge
  • Medicine
  • AJR. American journal of roentgenology
  • 2009
TLDR
The scientific literature, and specifically all prospective, controlled clinical trials, confirm that the five gadolinium chelates currently on the U.S. market with extracellular distribution—in order of their FDA approval, Magnevist, ProHance, Omniscan, OptiMARK, and MultiHance are safe. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 94 REFERENCES
The safety of gadolinium in patients with stage 3 and 4 renal failure.
  • I. Ergün, K. Keven, +4 authors O. Karatan
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2006
TLDR
An ARF can occur after gadolinium-based contrast agents in patients with moderate to severe chronic renal failure and risk factors for ARF include diabetic nephropathy and low GFR. Expand
Safety of gadolinium contrast angiography in patients with chronic renal insufficiency.
TLDR
It is found that rarely gadolinium-based contrast agents can cause acute renal failure in patients with underlying chronic renal insufficiency, and patients at high-risk should be identified and prophylactic measures should be taken to reduce the risk for nephrotoxicity. Expand
Gadodiamide administration causes spurious hypocalcemia.
TLDR
Gadodiamide administration causes spurious hypocalcemia, particularly at doses of 0.2 mmol/kg or higher and in patients with renal insufficiency. Expand
Nephrotoxicity of high‐dose gadolinium compared with iodinated contrast
TLDR
High‐dose gadolinium chelates are significantly less nephrotoxic than iodinated contrast, and none had gadolinia contrast‐induced renal failure despite the high gadoliniam dose and high prevalence of underlying renal insufficiency. Expand
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.
TLDR
The detection of gadolinium within tissue of NSF patients is supportive of an epidemiologic association between exposure to gadolinia-containing contrast material and development of disease. Expand
Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.
TLDR
The author of a recent article has suggested that administration of intravenous contrast material for magnetic resonance (MR) imaging (ie, gadolinium chelates) has been associated with a small cluster of patients with NSF in Austria (five of nine imaged patients). Expand
Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.
TLDR
It is concluded that GCCA exposure is a major risk factor for NSF in the ESRD population and gadolinium exposure should be avoided in patients with E SRD. Expand
Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.
TLDR
It is shown that gadodiamide plays a causative role in nephrogenic systemic fibrosis, and seven patients became severely disabled, and one died 21 mo after exposure. Expand
Case-control study of gadodiamide-related nephrogenic systemic fibrosis.
TLDR
Increasing cumulative gadodiamide exposure, high-dose epoietin-beta treatment, and higher serum concentrations of ionized calcium and phosphate increase the risk of gaddiamide-related nephrogenic systemic fibrosis in renal failure patients. Expand
Gadolinium-based contrast media may be nephrotoxic even at approved doses
TLDR
G gadolinium-based contrast media can cause contrast medium-induced nephropathy even at doses below 0.2 mmol/kg body weight in patients with multiple risk factors. Expand
...
1
2
3
4
5
...